COMPREHENSIVE OVERVIEW OF PROCESS VALIDATION IN PHARMACEUTICAL MANUFACTURING: ENSURING QUALITY AND COMPLIANCE IN INDUSTRY 4.0

Mohamed Hashim M F[1]*, K. Kathiresan[2]

[1]*M.Pharm (PQA) Student, Department of Pharmacy, FEAT, Annamalai University, Annamalainagar, Chidambaram-608002,Tamilnadu , India.

E-mail: farookhashim25@gmail.com, Mobile no: +91 9345570092

[2]Associate Professor, Department of Pharmacy, FEAT, Annamalai University, Annamalainagar, Chidambaram-608002, Tamilnadu, India.

Corresponding Author
Mohamed Hashim M F, M.Pharm (PQA) Student, Department of Pharmacy, FEAT, Annamalai University, Annamalainagar, Chidambaram-608002, Tamil Nadu, India
E-mail: farookhashim25@gmail.com, Mobile no:+91 9345570092

ABSTRACT

Process Validation (PV) is a critical component of Good Manufacturing Practice (GMP) in pharmaceutical production. It provides documented evidence that a manufacturing process consistently meets quality and purity standards. Process validation involves data collection and the process validation framework involves a three-stage analysis: process design, process qualification and ongoing process verification (as per 2011 USFDA guidelines). As the pharmaceutical industry embraces innovative technologies like Industry 4.0, process validation will become increasingly crucial in ensuring the quality, reliability, and consistency of pharmaceutical products.

KEY WORDS

Process validation, GMP, qualification

INTRODUCTION

PV is essential for licensing biologics, vaccines, and therapeutic proteins. It involves multiple stages, including:

1. Upstream processes (fermentation or cell culture).
2. Downstream processes (recovery, purification, modification and formulation).
3. Drug product manufacturing (final fill-and-finish steps).

Process validation serves as documented evidence that a procedure consistently produces a high-quality product that aligns with specific criteria, regulatory guidelines, and quality benchmarks. The main objective is to ensure the process consistently delivers the intended product quality, confirming its reliability and consistency.[1,2,3]

Conducting PV requires substantial time and effort, with careful focus on study design, execution and analysis. Regulatory agencies like the US FDA and other global bodies emphasize validation as part of their GMP requirements.[4]

Within pharmaceutical organizations, validation plays a vital role in supporting a company's commitment to quality assurance. It serves as a quality assurance tool, verifying the reliability of equipment systems, manufacturing processes, software and testing methods.[5]

GENERAL REQUIREMENTS AND CONSIDERATION

ROLES AND RESPONSIBILITIES

PV typically takes place later in the development cycle, after the product's activity and safety have been demonstrated in clinical trials. By the time process validation begins, substantial knowledge about the process and product has already been gathered.

Quality Control (QC) is responsible for conducting assay for release materials during both clinical development and commercial production. QC laboratories operate under GMP standards and are overseen by a separate quality organization.

In large pharmaceutical companies with multiple commercial products, a Manufacturing Sciences and Technology (MSAT) team is often formed. This team:

1. Provides technical expertise for commercial manufacturing processes.
2. Oversees and controls clinical manufacturing processes.
3. Serves as the primary link between manufacturing and other departments, such as R&D, quality, and regulatory affairs.

The MSAT (Manufacturing Science and Technology) team is vital in guaranteeing the technical robustness and efficiency of manufacturing processes, which is essential for producing high-quality products.

DOCUMENTATION

Implementing and robust documentation system is vital for tracking process and product information throughout the product lifecycle. In GMP facilities, a stringent documentation system is mandatory, overseen by the quality organization.

Key components of this system include:

1. Batch records
2. Raw material specifications

3. Assay specifications
4. Release specifications

PV activities must adhere to quality-approved protocols, which outline predetermined acceptance criteria, ensuring compliance and consistency.

EQUIPMENT AND FACILITIES

Commercial process validation must occur in a GMP-compliant facility, utilizing equipment and utilities subject to rigorous monitoring and maintenance.

The facility must have:
1. Documented change control systems
2. Established cleaning procedures

PV and cleaning validation for the new process are typically conducted simultaneously, ensuring a controlled and compliant environment.

PV campaign typically represents the initial execution of the commercial-scale process or its transfer to a new site, differing from clinical production. Development runs are crucial as they:
1. Provide valuable process insights
2. Enable adjustments to batch records
3. Enhance operational efficiency

These development runs facilitate a smooth transition to commercial-scale production.

Minimizing variations in raw materials is essential for ensuring a seamless transition as the process progresses from development to clinical and commercial production.

VALIDATION TEAM AND RESPONSIBILITIES

1. Reviews, updates, and approves validation deliverables and plans for each project.
2. Ensures compliance with the project's validation strategy and alignment with the company's overall validation master plan throughout the validation process.
3. Provides guidance, evaluates changes, and grants approval for modifications.
4. Analyze test results and provides recommendations for documentation and publication. [6,7]

GOALS

1) Validating equipment is crucial for both the manufacturing process and the specific equipment used.

2) Through validation, process parameters and control measures are established to ensure reliability.
3) This reduces the necessity for comprehensive process controls and extensive final product testing.
4) The aim to establish a dependable and strong manufacturing process and strong manufacturing process that consistently produces pharmaceutical products that meet predetermined quality standards for purity, identity, and potency, all while minimizing variability. It facilitates the identification of potential risks and worst case enabling proactive mitigation strategies to ensure the manufacture of high-quality products.
5) Validation enhances a deeper understanding of the system, its constituent parts, and their in interdependencies, ensuring a more robust and reliable process.
6) Effective validation minimizes the risk of regulatory nonconformance, ensuring adherence to applicable standards and guidelines.
7) It minimizes the need for extensive process controls and final product testing.
8) It contributes to lowering production costs.
9) Examining process variations provides valuable insights, enabling the identification of opportunities and control.[8]

ROLES OF PROCESS UNDERSTANDING

The US FDA's 1987 Process Validation Guidance consolidated industry best practices, defining process validation as generating documented evidence to ensure confidence in a process's ability to consistently produce a high quality products.

The fundamental concepts presented were as follows:
1. Qualification of facilities and equipment.
2. Prospective and concurrent validation.
3. Requalification.
4. Comprehensive documentation.
5. Conducting multiple successful runs to showcase process capability.

The guidance stressed the importance of adopting a logical, risk-based, and scientific methodology. The 2011 updated guidance broadened its scope to include the assessment of data across the entire process life cycle, establishing scientific proof of a process's ability to consistently produce quality products.[9]

PHASES OF VALIDATION

A.Design Qualification (DQ):

DQ usually serves as the first step in validating new facilities, systems, or equipment. This process entails verifying and documenting that the design aligns with Good Manufacturing Practice (GMP) regulations. It formally confirms that production facilities and equipment are designed to meet set requirements.

Key aspects of design qualification include:
1) Adherence to legal requirements and GMP standards.
2) Meeting performance criteria.
3) Reliability and efficiency.
4) Accessibility and maintenance of essential instruments and equipment.[10]
5) Consideration of environmental and safety impacts.

B. Installation Qualification (IQ):

IQ provides documented assurance that the installation of process equipment, supplementary systems, and facilities aligns with both the manufacturer's specifications and supplier recommendations. This validation is crucial for new, updated, or relocated equipment and systems.

Key aspects verified during Installation Qualification (IQ) are:
1.Equipment design features, including material compatibility and cleanability.
2.Installation encompassing utilities, functional operation, and electrical wiring.
3. Scheduled cleaning, calibration, and preventive maintenance.
4. Software documentation, ensuring accuracy and completeness.
5. Software documentation, ensuring accuracy and completeness.
6. Spare parts inventory, confirming availability and accessibility.
7. Environmental factors, such as humidity, temperature, and cleanroom standards, to ensure compliance with specified requirements.
8. Detailed description of the equipment.
9. Functional specifications of the facility.

C.OPERATIONAL QUALIFICATION (OQ):

OQ needs to follow a sanctioned protocol, emphasizing the identification of crucial operational parameters for systems and equipment.

Key aspects of OQ encompass are :
1.process control factors such as time, temperature, pressure, line speed, and setup conditions to guarantee peak performance.
2.Parameters of software.
3.Raw material description.
4.Standard operating procedures for processes.
5.Material handling requirements.

The use of statistically sound methods, like screening experiments, to optimize the process.[11]

D.PERFOFRMANCE QUALIFICATION (PQ):

Completion of IQ and OQ is crucial before proceeding to PQ.

Key PQ factors include:
1. Adhering to the product and process guidelines set during the OQ phase.
2. Ensuring the quality and acceptability of the product.
3. Checking that the process can consistently meet OQ standards.
4. Assessing the process for long-term repeatability, stability and reliability.[12]

E. RE-QUALIFICATION:

Equipment modifications or relocations require re-qualification, which involves a thorough evaluation and approval process through the change control procedure to ensure continued compliance and validation.[13]

PROCESS LIFE CYCLE APPROACH

The FDA's 2011 guidance presents a three-phase strategy for process validation:
stage 1: Crafting the process design and pinpointing essential variables.
stage 2: Executing control measures and qualifying facilities, equipment, and systems.
stage 3: Continuously monitoring and assessing the process to maintain consistent reliability and effectiveness.



Figure 1: Three-Stage Life Cycle Approach to Process Validation, illustrating a continuous process validation framework.

Quality assurance has undergone significant transformation:
Pre-1970s:Emphasis product testing.

1980s-2010:Focus qualification and validation tests.

Present day: Holistic approach from process development to commercial manufacturing, emphasizing process understanding and identification of critical factors.

This approach prioritizes building confidence through effective process design instead of depending solely on testing. Additionally, there is a greater emphasis on preventing failures rather than merely detecting them.[14]

PROTOCOL FOR VALIDATION:

1. Establish the goals and boundaries of the study.
2. Detail the roles, qualifications and duties of the validation team.
3. Identify the types of validation, including prospective, concurrent, retrospective and re-validation.
4. Decide on the criteria for selecting batches as well as the quantities needed.
5. Enumerate the operational parameters for equipment, covering both typical and worst-case scenarios.
6. Incorporate IQ and OQ results for essential equipment.
7. Outline calibration requirements for measurement tools.
8. Highlight important process variables and their acceptable tolerance ranges.[15]

CHALLENGES TO REALIZING INDUSTRY 4.0 IN PHARMACEUTICAL MANUFACTURING:

Transitioning to Industry 4.0 requires adopting advanced technologies while navigating regulatory, technical, and logistical hurdles.

Key challenges include:

*Institutional and regulatory knowledge tied to existing technologies

*High development costs and uncertain regulatory outcomes

*Lack of industry precedents

*Companies often adopt a "wait-and-see" approach, observing competitors' strategies before proceeding.

AFTER APPROVAL, PROCESS MONITORING

- The validation process should be approached from a life-cycle perspective. Just carrying out PV without continuing to observe the procedure and search for opportunities for improvement is no longer adequate.
- A monitoring scheme should be implemented following permission to show that the procedure is under control, according to recent guidelines from the health authorities .

- In addition to recording release-testing outcomes, the monitoring program should be connected to the Annual Product Review.
- Supporting the validated controlled process operation is the goal of the monitoring program. It might be necessary to periodically check a subset of the input and output parameters that were confirmed during the first PV campaign.
- It's also advisable to use a statistical method to comprehend process variability. While identifying additional sources of variability, testing frequency should be taken into account. For instance, variations across production campaigns could be greater than those within a campaign.
- Monitoring authorized processes that are operated at several locations requires the use of a process monitoring program.

PROCESS TRANSFER

Process transfer takes place at every stage of a product's life cycle. This happens during the early stages of development when the process is scaled up and moved from the R&D department to the GMP organization.

Although early development does not have any particular validation criteria, it is nonetheless crucial to explicitly record the process knowledge acquired at these stages since doing so would increase process comprehension. Revalidation at the location and resubmission to the regulatory bodies are necessary when transferring an approved, commercial procedure.

While there are numerous ways to finish the transfer and secure clearance, proving process and product comparability will be a common element. It could be necessary to conduct extra monitoring if the same process is being carried out at several locations to guarantee that the procedures followed and the final product are consistent.

LOGISTICAL CHALLENGES

Challenges in the implementation of Industry 4.0 will present logistical challenges for both industry and regulators, and certain situations, they might be competing for the same limited resources. Manufacturers and regulators must handle various data, computing, and automation hazards through innovations and cultural shifts before fully implementing Industry 4.0 concepts.

To implement AI in pharmaceutical manufacturing, a variety of abilities beyond the conventional biology, chemistry and process engineering will be required.

REGULATORY CHALLENGES

Regarding regulatory barriers, navigating existing regulatory frameworks can present significant challenges to technological innovation. The absence of regulatory precedents often prompts the industry to adhere to traditional processes, even when newer methods could reduce overall regulatory demands and enhance product quality in the long term.

The adoption of Industry 3.0 technologies, such as adaptive control systems and continuous manufacturing, has exposed limitations in traditional process validation methods. Additionally, regulatory complexities pose significant challenges:

*Navigating differing global regulatory requirements for emerging manufacturing technologies

*Submitting applications across multiple jurisdictions with varying standards

International regulatory alignment on advanced manufacturing practices could help mitigate these uncertainties and facilitate smoother adoption for manufacturers.[16]

CONCLUSION

PV is a critical practice in pharmaceutical companies, ensuring the quality of final products. By following USFDA guidelines, organizations gain a deeper understanding of their products and processes, minimizing waste, rejections, and failures. This approach also fosters continuous improvement throughout the product life cycle. Ultimately, validation is essential for ensuring product quality, driving quality assurance, and optimizing cost efficiency.

Industry 4.0 technologies are have the capacity to transform pharmaceutical manufacturing and logistics through cutting-edge advancements in computing, robotics, autonomous systems, and digitalization. These innovations will significantly enhance supply chains, production processes, distribution networks, and inventory systems. The future "smart factory" will feature autonomous capabilities, enabling greater production flexibility and agility. However, full adoption of Industry 4.0 requires overcoming challenges related to data management, computing infrastructure, and automation integration. Process validation serves as a scientific method for ensuring that processes consistently deliver high-quality results. Raising awareness of validation practices will help maintain the reproducibility and quality of products, meeting regulatory standards globally.

REFERENCES

[1] FDA (1987) Guideline on General Principles of Process Validation. Silver Spring, MD: United States Food and Drug Administration.

[2] FDA (1997) Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Silver Spring, MD: United States Food and Drug Administration.

[3] FDA (2008) Guidance for Industry. Process Validation: General Principles and Practices. Silver Spring, MD: United States Food and Drug Administration.

[4] World Health Organization 2003. Committee on specifications for pharmaceutical preparations, GMP for pharmaceutical products. WHO Tech Report. 82, 14-79.

[5] Guideline on general principles of process validation. Centre for drug evaluation and research, FDA. www.fda.gov/cder/guidance/pv/htm.

[6] Ketaki S. Shinde, Dr. R. C. Doijad1, Dr. J. S. Mulla1 and Sachin S. Mali, “Basic Aspects of Pharmaceutical Process Vali-dation of Solid Dosage Forms: Quality Assurance Point Of View”, European Journal of Pharmaceutical and Medical Re-search, Vol 9, Issue 3, 2022.

[7]Validation and Qualification pharma facilities https://www.pharmamanufacturing.com/articles/2016/validation-and-qualification-in pharma-facilities/

[8] Todkar VS, Lade MS, Patil KS, D’souza JI Computerized System Valida-tion: Introduction Implementation and Regulations- A Review International Journal for Pharmaceutical Research Scholars (IJPRS) V-3, I-3, 2014 ISSN No: 2277 – 7873.

[9] FDA, 1987. Guidelines on General Principles of Process Validation. Food and Drug Administration.

[10] Mohankumar M., Sivakamasundari G.; A Review on Pharmaceutical Validation and Its Importance and Imputation. International Research Journal of Pharmacy. 2021;12(10):2326.

[11] Telange D.; Bioanalytical Method Validation: A Review Article. Journal of Analytical & amp; Bioanalytical Techniques. 2010; 1(1): 88-93.

[12] Swati R., Mansi P., and Aditya P.; Analytical Method Development and Validation: A Concise Review. International Journal of Pharmacy and Biological Sciences, 2021;11(1): 9-16.

[13] Choudharya A.; A Review on Pharmaceutical Validation and Its Implications. Journal of Medical Pharmaceutical and Allied Sciences.2021; 10(6): 3951-3961.

[14] PDA, 2013. Technical Report No. 60 Process Validation: A Lifecycle Approach.

[15] Alka N Choudhary, Tanya Sehgal, "A review on pharmaceutical validation and its implications", Journal of medical pharmaceutical and allied sciences, Volume 10 Issue 6, 1927, 2021, Page-3951-3959.

[16] Pwc,2015. Next Manufacturing: Industry 4.0. https://www.pwc.com/us/en/industries/ industrial-products/next-manufacturing.html. Accessed.